Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ARRIS - Another partner -- Ignore unavailable to you. Want to Upgrade?

To: John Dwyer who wrote (268)	12/2/1997 8:49:00 PM
From: Miljenko Zuanic	Respond to of 353

Hi John: Thanks for your view of the Delta PI. Ended we all lost few nerves waiting patent and explanation of the Delta advantage in PI designee. I do not have read claims and whole patent, but from patent abstract: >>Serine protease inhibitors are provided comprising compounds having a P site binding moiety and a divalent cation(s) chelating moiety which are pre-prepared as divalent cation(s) complexes or combined with the serine protease in the presence of divalent cation(s). The compounds are shown to have high inhibitory activity when complexed to divalent cation(s) and find use in various processes associated with serine protease isolation and inhibition.<< appears that inhibitor is organic complex between small molecule and divalent cation. This approach is new, for me. The question: *Is metal ion (naturally available: Zn, Mg, Co,...) present in cells/plasma or is incorporated during formulation/manufacturing of the PI complex, is actually my concern. Giving the facts that metals complex are much stronger (binding energy) than H-bonds complex, this combination, I guess, have promising future. I do not have biology training to judge physiological application/problems, but to me sound interesting and attractive. More when I read full patent/announced manuscript in journal. mz